Bezafibrate alone is an effective first-line therapy for primary sclerosing cholangitis: A case report

Japanese Journal of Gastroenterology

Volumn 103, Issue 6, 2006, Pages 643-649

  Gondoh, Kazuhisa ^a   Ono, Tetsujiro ^d   Miyakoda, Kenji ^d   Mukasa, Michita ^d   So, Atsushi ^d   Imamura, Kenichiro ^b   Sata, Michio ^c  

^a Gondoh Medical Clinic

^b Internal Medicine of Fukuoka Prefectoral Yanagawa Hospital   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BEZAFIBRATE; IMMUNOGLOBULIN G4;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; HYPERLIPIDEMIA; PRIMARY SCLEROSING CHOLANGITIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTILIPEMIC AGENTS; BEZAFIBRATE; CHOLANGITIS, SCLEROSING; FEMALE; HUMANS; HYPERLIPIDEMIAS; MIDDLE AGED;

EID: 33745642992     PISSN: 04466586     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Martins E, Graham AK, Chapman RW, et al: Elevation of gamma delta T lymphocytes in peripheral blood and livers of patients with primary sclerosing cholangitis and other autoimmune liver disease. Hepatology 23; 988-993: 1996
2. Takikawa H, Takamori Y, Tanaka A, et al: Analysis of 388 cases of primary sclerosing cholangitis in Japan Presence of a subgroup without pancreatic involvement in older patients. Hepatol Res 29; 153-159: 2004
3. Kita R, Kita-Sasai Y, Hanaoka I, et al: Benefical effect of bezafibrate on primary sclerosing cholangitis (three case reports). Am J Gastroenterol 97; 1849-1851: 2002
4. Kurihara T, Maeda A, Shigemoto M, et al: Efficacy of bezafibrate in a patient with primary sclerosing cholangitis. J Gastroenterol 38; 300-301: 2003
5. Hamano H, Kawa S, Horiuchi A, et al: High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 344; 732-738: 2001
6. Chapman RW: The management of primary sclerosing cholangitis. Curr Gastroenterol Rep 5; 9-17: 2003
7. Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 336; 691-695: 1997
8. Poupon RE, Balkau B, Eschwege E, et al: A multicenter controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 324; 1548-1554: 1991
9. Paumgartner G, Beuers U: Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36; 525-531: 2002
10. Iwasaki S, Tsuda K, Ueta H, et al: Bezafibrate may have a beneficial effect in precirrhotic primary biliary cirrhosis. Hepatol Res 16; 12-18: 1999
11. Staels B, Koenig W, Habib A, et al: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393; 790-793: 1998
12. Devchand PR, Keller H, Peters JM, et al: The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384; 39-43: 1996
13. Calabresi L, Franceschini G, Sirtori CR, et al: Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. BBRC 238; 61-65: 1997